University of Sydney, Australia.
University of Sydney, Australia.
Radiother Oncol. 2018 Apr;127(1):6-11. doi: 10.1016/j.radonc.2018.01.001. Epub 2018 Feb 7.
Until now, real-time image guided adaptive radiation therapy (IGART) has been the domain of dedicated cancer radiotherapy systems. The purpose of this study was to clinically implement and investigate real-time IGART using a standard linear accelerator.
MATERIALS/METHODS: We developed and implemented two real-time technologies for standard linear accelerators: (1) Kilovoltage Intrafraction Monitoring (KIM) that finds the target and (2) multileaf collimator (MLC) tracking that aligns the radiation beam to the target. Eight prostate SABR patients were treated with this real-time IGART technology. The feasibility, geometric accuracy and the dosimetric fidelity were measured.
Thirty-nine out of forty fractions with real-time IGART were successful (95% confidence interval 87-100%). The geometric accuracy of the KIM system was -0.1 ± 0.4, 0.2 ± 0.2 and -0.1 ± 0.6 mm in the LR, SI and AP directions, respectively. The dose reconstruction showed that real-time IGART more closely reproduced the planned dose than that without IGART. For the largest motion fraction, with real-time IGART 100% of the CTV received the prescribed dose; without real-time IGART only 95% of the CTV would have received the prescribed dose.
The clinical implementation of real-time image-guided adaptive radiotherapy on a standard linear accelerator using KIM and MLC tracking is feasible. This achievement paves the way for real-time IGART to be a mainstream treatment option.
到目前为止,实时图像引导自适应放疗(IGART)一直是专门的癌症放疗系统的领域。本研究的目的是使用标准线性加速器临床实施和研究实时 IGART。
材料/方法:我们为标准线性加速器开发并实现了两种实时技术:(1)千伏分时段监控(KIM),用于找到目标,以及(2)多叶准直器(MLC)跟踪,用于将辐射束对准目标。8 例前列腺 SABR 患者接受了这种实时 IGART 技术治疗。测量了可行性、几何精度和剂量学保真度。
实时 IGART 治疗的 40 个分次中有 39 个成功(95%置信区间 87-100%)。KIM 系统的几何精度在 LR、SI 和 AP 方向上分别为-0.1±0.4、0.2±0.2 和-0.1±0.6mm。剂量重建表明,实时 IGART 比没有 IGART 的情况下更能准确地复制计划剂量。对于运动幅度最大的分次,实时 IGART 可使 100%CTV 接受规定剂量;而没有实时 IGART 的情况下,只有 95%CTV 会接受规定剂量。
使用 KIM 和 MLC 跟踪在标准线性加速器上实施实时图像引导自适应放疗是可行的。这一成就为实时 IGART 成为主流治疗选择铺平了道路。